CJC-1295 (DAC)
Also known as: CJC-1295 with Drug Affinity Complex
Molecular Overview
CJC-1295 with DAC couples a modified GHRH fragment to a maleimide linker that binds serum albumin, a design studied for prolonged half-life in early clinical research.
Mechanistic Background
Albumin conjugation extends circulating persistence of the GHRH analog in experimental models.
What Researchers Study
Early-phase human pharmacokinetic studies were published in the 2000s; later development did not proceed.
Evidence Landscape
Current evidence level: EARLY TRANSLATIONAL. Preclinical evidence does not equate to demonstrated human efficacy.
Research Limitations
Development was discontinued; contemporary human data are lacking.
Scientific References
Research Use Only
Molecularix Biolabs provides research materials for legitimate laboratory research. Information in this Research Library is provided for educational and scientific reference purposes and is not medical advice, treatment guidance, or a recommendation for human or veterinary use.